SCPHARMACEUTICALS INC. Deferred Tax Assets, in Process Research and Development
SCPHARMACEUTICALS INC. had Deferred Tax Assets, in Process Research and Development of $24.38 million as of 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2025-03-19
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $24.38M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $27.72M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $30.98M.
- 2021-12-31: Deferred Tax Assets, in Process Research and Development $29.53M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2024-12-31 | $24.38M 10-K · filed 2025-03-19 |
| 2023-12-31 | $27.72M 10-K · filed 2025-03-19 |
| 2022-12-31 | $30.98M 10-K · filed 2024-03-13 |
| 2021-12-31 | $29.53M 10-K · filed 2023-03-22 |
| 2020-12-31 | $23.98M 10-K · filed 2022-03-22 |
| 2019-12-31 | $19.29M 10-K · filed 2021-03-23 |
| 2018-12-31 | $14.23M 10-K · filed 2020-03-24 |
| 2017-12-31 | $10.45M 10-K · filed 2019-03-21 |